Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc.

4.01
USD
+0.19
(+5.08%)
-0.04EPS
108.80MMarket Cap
Feb 10Next Earn

Q2 FY2027 · Earnings Call TranscriptNovember 12, 2026

Operator

Good day everyone, and welcome to Medexus Pharmaceuticals second quarter 2027 conference call. At this time, all participants are placed on a listen-only mode.

If you have any questions or comments during the presentation, you may press *1 on your phone to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, Victoria Rutherford.

Ma'am, the floor is yours.

Victoria Rutherford

Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals second fiscal quarter 2027 earnings call.

On the call this morning are Ken d'Entremont, Chief Executive Officer, and Brendan Bushman, Chief Financial Officer. If you have any questions after the conference or would like further information about the company, please contact Adelaide Capital at 480-625-5772.

I would like to remind everyone that this discussion will include forward-looking information as defined in Canadian securities laws that is based on certain assumptions that Medexus believes to be reasonable in the circumstances, but is subject to risks and uncertainties. Actual results may differ materially from historical results or results anticipated by the forward-looking information.

In addition, this discussion will also include non-GAAP measures, such as adjusted EBITDA, adjusted gross margin, net debt, and related measures, which do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. For more information about forward-looking information and non-GAAP measures, including reconciliations, please refer to the company's MD&A, which, along with the financial statements, is available on the company's website at www.medexus.com and on SEDAR+ at www.sedarplus.ca.

As a reminder, Medexus reports on a March 31st fiscal year basis. Medexus reports financial results in US dollars, and all references are to US dollars unless otherwise specified.

I would now like to turn the call over to Ken d'Entremont.

Ken d'Entremont

Thank you, Victoria, and good morning, everyone. We're pleased with our second quarter performance and the continued strength of our business, supported by solid adjusted EBITDA, healthy operating cash flow, and the company's strong financial position.

A key contributor to this quarter's performance was our continued progress in the commercialization of Grafapex, and we remain encouraged by the significant growth opportunity ahead. During fiscal Q2 '27, Grafapex generated $5.7 million in product-level net revenue compared to approximately $3.8 million in related personnel and infrastructure investments, plus $0.7 million in cost of product and amortization in the same period, reflecting continued progress in scaling the product.

With a dedicated sales team deployed and early commercial indicators trending positively, we believe we are well positioned to accelerate awareness and adoption. This progress, in particular our expanded commercial capabilities, reinforces our confidence that product-level net revenue of Grafapex for fiscal year '27 will be between $30 and $32 million US dollars.

We are encouraged by the early indicators, and we have seen and believe our expanded commercial presence positions us well to maintain momentum throughout the remainder of the fiscal year. Commercial adoption also continues to progress well.

Wholesaler data as of September 30th, 2026 shows that 86 individual healthcare institutions have already ordered Grafapex for procedures in their institutions, and 38 of those institutions have placed multiple orders in the most recent completed 6-month period. Ordering by healthcare institutions and payer coverage and access trends have been highly encouraging, and the early indicators of patient-level demand continue to reinforce the value proposition Grafapex brings to patients, providers, and payers.

Based on the continued commercial traction we're seeing, we continue to expect Grafapex to achieve annual product-level net revenue of approximately $100 to $175 million within five years after commercial launch. Turning to our overall financial results, net revenue for fiscal Q2 '27 increased to $29.1 million from $24.7 million in the prior-year period, while adjusted EBITDA increased to $5.1 million from $4.4 million.

We also generated net income of $0.8 million compared to a net loss of $0.3 million in the prior-year period, and operating income improved to $2.4 million, up from $1.4 million. Beyond Grafapex, our portfolio of established products continues to provide a solid foundation for the business, supported by sustained total underlying demand across key products.

This stability, together with our stable financial position, allows us to remain focused on our growth opportunities, most notably the continued commercialization of Grafapex and the longer-term potential of UM171 cell therapy in Canada. We believe these opportunities position Medexus well for its next phase of growth as we continue to execute on our strategic plan, generate operating cash flow, and invest in creating long-term value.

I'll now turn the call over to Brendan, who will discuss our financial results in more detail. Brendan?

Brendan Bushman

Thank you, Ken. Our second quarter results reflected the continued momentum of Grafapex, the stability of our portfolio of established products, and the strength of our financial position, supported by growing revenues, solid adjusted EBITDA, and healthy operating cash flows.

As Ken mentioned, we generated $5.7 million of product-level net revenue from Grafapex in fiscal Q2 '27, and we continue to expect increasing Grafapex product-level net revenue to have a positive effect on operating cash flow. Product-level performance of Grafapex continues to reflect meaningful growth.

Underlying patient demand was $5.6 million for fiscal Q2 '27, representing growth of 16% compared to $4.8 million for fiscal Q1 '27, and 156% compared to $2.1 million for fiscal Q2 '26. Turning to the full quarterly results, total net revenue for fiscal Q2 '27 was $29.1 million.

This represents an increase of $4.4 million compared to $24.7 million for the same period last year. The $4.4 million year-over-year net revenue increase was primarily due to an increase in product-level net revenue from Grafapex and Ixinity, among other factors.

Gross profit was $16.3 million for fiscal Q2 '27 compared to $13.8 million for the same period last year. Gross margin was 55.9% for fiscal Q2 '27 compared to a gross margin of 55.7% for the same period last year.

Adjusted gross margin was 64% compared to 65.2% for the same period last year. Year-over-year changes in gross margin and adjusted gross margin are primarily due to the changes in the relative contribution of product-level net revenue, in particular an increasing level of net sales of Grafapex and a higher cost of sales of products for Ixinity in fiscal year '27.

Selling, general, and administrative expenses were $13.3 million for fiscal Q2 '27 compared to $11.9 million for the same period last year. Adjusted EBITDA was $5.1 million for fiscal Q2 '27, an increase of $0.7 million compared to $4.4 million for the same period last year.

The $0.7 million year-over-year adjusted EBITDA increase was primarily due to the $5.7 million of product-level net revenue from Grafapex for fiscal Q2 '27 exceeding the $3.8 million of Grafapex personnel and infrastructure investments, plus $0.7 million of cost of sales of products before amortization in the same period. This improvement was partially offset by the impact of generic competition on Rupall.

Net income was $0.8 million for fiscal Q2 '27, an increase of $1.1 million compared to a net loss of $0.3 million in Q2 '26. Cash provided by operating activities was $5.4 million for fiscal Q2 '27, an increase of $2.1 million compared to $3.3 million of cash provided by operating activities for the same period last year.

Part of this improvement is due to working capital and payment timing, although we continue to expect increasing Grafapex product-level net revenue to have a positive effect on operating cash flow over time. As of September 30th, 2026, our net debt was $17.9 million, an increase of $2.1 million compared to $15.7 million as at March 31st, 2026.

Net debt to adjusted EBITDA was 0.97 times as of September 30th, 2026. We remain in a strong position, supported by healthy operating cash flows and the continued contribution of our overall portfolio to company performance.

While quarterly results may vary, we believe the foundation we have built over the past quarters will provide us with the flexibility to support the continued commercialization of Grafapex and pursue opportunities that drive long-term growth. Operator, we will now open the call to analyst questions.

Operator

Certainly. Everyone, at this time we will be conducting a question-and-answer session.

If you have any questions or comments, please press *1 on your phone at this time. We do ask that while posing your question, please pick up your handset if you're listening on speakerphone to provide optimum sound quality.

Once again, if you have any questions or comments, please press *1 on your phone. Your first question is coming from Scott Henry from Alliance Global.

Your line is live.

Scott Henry

Thank you, and good morning. First, great execution.

You've really strung together a lot of solid quarters in the Grafapex launch. That brings me to my question is, obviously Grafapex is launching very well, but looking at the numbers, to get to 30 to 32 is going to take a significant jump from what we saw in the first half of the year, not just continuation of trends.

What are you seeing that gives you confidence that we're not just continuing to have the good things happen, but they're actually going to accelerate? Just wanted to get a sense of that.

Thank you.

Ken d'Entremont

Thank you, Scott. Great question.

I'm sure that's on a lot of people's minds. What we're seeing in the field is very much kind of what expected.

Remember when we launched this product, there was no experience in the US with this drug. All the development had been done elsewhere, with the exception of one center, which was Fred Hutch.

We clearly knew that we had to build belief within the whole market across the 170-some-odd institutions. We've been doing that, and doing that successfully.

I think that's what's driven our revenues to this point. We've now gotten to a point where there is evidence that's being generated from the US market that will be shared beginning at ASH, and then obviously through Tandem.

That is what gives us strong belief that we will see an acceleration in our revenues as real-world evidence from the US market starts to be shared. We really think that's what will drive institutions that haven't yet adopted the drug to adopt it, and those who are already starting to use it to use more.

We've got a high degree of confidence that the drug will continue to perform well, and with our execution that has been solid to this point, we will see that growth that we expect.

Scott Henry

Sort of a follow-up to that, do you expect most of that inflection in the fiscal third quarter, your December quarter, or next year's March quarter? Along those lines, we're already halfway through the December quarter, how are you feeling about when we should see that significant continued inflection?

Ken d'Entremont

I think it'll be spread over the two quarters. ASH is early December this year.

There'll be significant evidence presented there, which will start to accelerate, and then through fourth quarter, I think we'll see strong uptake. We're seeing progress now, with more and more institutions coming on board and sharing their experience with their colleagues, that clearly supports our launch.

Scott Henry

Great. Thank you for that color.

With regards to UM171, obviously you have the Canadian rights, I believe someone else just picked up the European rights, what are your thoughts on the timeline of what could happen with the US rights as, and is that likely going to indicate, what happens for the future clinical pathway of the product?

Ken d'Entremont

As evidenced by the fact that we licensed it for Canada, I think we're strong supporters of the product. We see a good potential for the product, but I can't really comment on licensing discussions that might be ongoing.

Scott Henry

Fair enough. One just clerical question: did I see this right, were Canadian sales $5,932,000 in both Q1 and Q2?

I just didn't know if that was a typo.

Ken d'Entremont

Brendan?

Brendan Bushman

Yeah. No, that should be correct.

Scott Henry

Okay. It's unusual.

All right, thank you for taking the questions.

Operator

Thank you. Once again everyone, if you have any questions or comments, please press * then 1 on your phone.

Your next question is coming from Andre Uddin from Research Capital. Your line is live.

Andre Uddin

Thanks, operator. Hi Ken and Brendan, nice quarter.

Just need a little bit more clarity, given that Zemcelpro received conditional marketing authorization from the European Commission, are you planning on using that dossier to file your NDS in Canada, or will you wait for more data, and when should we expect that filing to take place? Thanks.

Ken d'Entremont

Thanks, Andre. I think first step in Canada is getting clarity from Health Canada on what paths are available to us.

We would certainly be interested in using the path that was forged by ExCellThera in Europe, being able to make the product available for those patients who simply don't have a donor, but we don't yet know if that path is available to us in Canada. That's why I think when we licensed it, we gave kind of a range of launch dates, which was between 2028 and 2031, I believe.

Andre Uddin

That's fair. Just if we're looking at the prescription trends for Grafapex, they look strong.

Should we expect similar seasonal sales patterns for Grafapex next year?

Ken d'Entremont

A really good question. We've been trying to tease out seasonality on Grafapex for a while.

As we get more and more volume, it's becoming a little bit easier. There's not a really well-defined seasonality for this space other than I would say that when transplanters are not in the institution around holidays like the upcoming Thanksgiving period in the US, and then the Christmas period also, we do see a decline in number of transplants done.

No clear seasonality. I think non-malignant disease a little bit different, which is primarily children, where they would try to avoid the summer period.

There's a little bit of seasonality, but it's not overwhelming.

Andre Uddin

Thanks. That's it for me.

Operator

Thank you. That concludes our Q&A session.

I'll now hand the conference back to Ken d'Entremont for closing remarks. Please go ahead.

Ken d'Entremont

I'd like to thank you all for your participation. We're pleased with our performance through the first half of fiscal '27, and remain confident in the strength of our business and the opportunities ahead.

With continued progress in the commercialization of Grafapex, a resilient portfolio of established products, and a strong financial foundation, we believe Medexus is well positioned to execute on our growth strategy and create long-term value. We appreciate your continued interest and support, and thank you for joining us today.

Operator

Thank you, everyone. This concludes today's event.

You may disconnect at this time and have a wonderful day. Thank you for your participation.